Acurx Pharmaceuticals Inc. – Financial and Operational Update (as of 2026‑03‑13)
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) reported full‑year and fourth‑quarter results for the fiscal year ended December 31, 2025, and provided a detailed outlook for its antibiotic pipeline. The company’s primary focus remains the development of ibezapolstat, a novel agent targeting recurrent Clostridioides difficile infections (CDI).
1. Financial Highlights (FY 2025)
| Item | 2025 | 2024* |
|---|---|---|
| Net Cash, Cash Equivalents, and Marketable Securities | $21.4 million | $18.6 million |
| Cash‑Equivalent Liquidity at Fiscal Year‑End | $21.4 million | $18.6 million |
| Total Revenues | $0.0 million | $0.0 million |
| Operating Loss | $14.2 million | $12.3 million |
| Net Loss | $15.8 million | $13.4 million |
| Cash Burn (Q4 2025) | $4.7 million | $4.2 million |
| GAAP EPS (Q4 2025) | ‑$5.32 | — |
| Non‑GAAP EPS (Q4 2025) | — | — |
*Prior year figures are taken from the company’s 2024 filing.
The company reported a net loss of $15.8 million for FY 2025, driven primarily by research and development (R&D) expenditures and regulatory costs. Cash burn for the fourth quarter was $4.7 million, leaving the company with sufficient liquidity to support its ongoing clinical programs through at least Q2 2026.
2. Pipeline Update – Ibezapolstat
Acurx disclosed that it is preparing for a pivotal Phase 3 trial of ibezapolstat in patients with recurrent CDI, with enrollment expected to begin in the second half of 2026. The company highlighted the following milestones:
- Phase 2 Data – The Phase 2b study reported a 96 % cure rate in the intent‑to‑treat population, a result that has attracted significant investor attention.
- Trial Design – The forthcoming Phase 3 will compare ibezapolstat to vancomycin for the prevention of CDI recurrence.
- Regulatory Strategy – Acurx intends to pursue a breakthrough therapy designation to accelerate the review process.
The announcement of the Phase 3 plan, combined with the robust Phase 2 efficacy data, has led to a 218 % increase in the stock price over the past five days, as reported by TipRanks.
3. Research & Development Progress
Acurx continues to advance several clinical studies:
| Study | Status | Key Findings |
|---|---|---|
| IBZ‑C1 (CDI) | Phase 2b | 96 % cure rate |
| IBZ‑P1 (Pneumonia) | Phase 1 | Tolerable safety profile |
| IBZ‑S1 (Sepsis) | Preclinical | Promising antibacterial spectrum |
The company emphasized that the data supporting ibezapolstat’s safety and efficacy were “sufficiently robust to justify the next phase of development.”
4. Market Commentary
- Stock Performance – As of March 11 2026, the share price stood at $5.01, a sharp rise from the 52‑week low of $1.326. The recent 218 % jump reflects optimism surrounding the upcoming Phase 3 trial.
- Analyst Consensus – Analysts project a Q4 2025 EPS loss of $1.013 per share, an improvement over the previous year’s loss of $3.200. Revenue expectations remain unchanged at $0.0 million for the upcoming quarter.
- Investor Sentiment – Benzinga’s coverage highlighted the day’s trading activity, noting that the stock’s movement was driven largely by the clinical update rather than underlying earnings.
5. Outlook
Acurx forecasts continued R&D spending for 2026, with expected cash burn of $5–$6 million in the first half of the year. The company expects to maintain its liquidity position above $20 million, allowing it to pursue the Phase 3 trial without additional financing. No new revenue streams are anticipated in 2026, as the company remains in a pre‑commercial phase.
Key Takeaways
- Acurx reported a net loss of $15.8 million for FY 2025 but retains robust liquidity.
- The company is advancing a Phase 3 trial of ibezapolstat for recurrent CDI, following a 96 % cure rate in Phase 2b.
- Stock price surged 218 % in five days following the clinical update, reflecting strong market confidence in the upcoming trial.
- Analysts anticipate a smaller Q4 loss and no revenue growth for 2026, with continued investment in R&D.
